Contact
Member Login
Donate Now

Advocacy

the u.s. capital building

Call to Action 2020! Help Us Get Your Voice Heard for More Research Funding!

Leave a Comment / Advocacy, News / By

The Foundation for Peripheral Neuropathy is embarking on a new and heightened campaign to make more funding available for research on peripheral neuropathy. For 2020, we are building on our efforts from 2019 to increase our efforts and build awareness in both the Senate and the House of Representatives of the importance of including peripheral …

Call to Action 2020! Help Us Get Your Voice Heard for More Research Funding! Read More »

Peripheral Neuropathy Advocacy Update

Leave a Comment / Advocacy, News / By

In March 2019, the Foundation for Peripheral Neuropathy initiated an advocacy program to promote more government spending on peripheral neuropathy research through the DoD’s medical research fund. To learn more about the campaign, and what we did for the campaign, please read here. PN Advocacy Update We recently found out that the initial Senate version …

Peripheral Neuropathy Advocacy Update Read More »

the u.s. capital building

Call to Action! Help Us Get Your Voice Heard for More Research Funding!

1 Comment / Advocacy, News / By

Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington, D.C., confirmed that the president and Congressional leaders recently reached an important two-year budget deal, paving the way for the Senate to complete its spending bills in September. As a result, in early September, the …

Call to Action! Help Us Get Your Voice Heard for More Research Funding! Read More »

the u.s. capital building

Update on FPN’s Campaign to Get Peripheral Neuropathy Research in the US Budget

Leave a Comment / Advocacy, News / By

Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington DC, provided an update on FPN’s efforts to include peripheral neuropathy in the list of conditions and diseases eligible for research funding under the Department of Defense’s Peer-Reviewed Medical Research Program. The Campaign: Get PN …

Update on FPN’s Campaign to Get Peripheral Neuropathy Research in the US Budget Read More »

Add your voice to FPN’s to encourage more government research spending on peripheral neuropathy

Leave a Comment / Advocacy, News / By

Your voice can help increase spending for research on peripheral neuropathy! The Foundation for Peripheral Neuropathy has initiated an advocacy program to promote more government spending on peripheral neuropathy research through a Defense Department Fund that supports medical research. Each year, the United States Senate agrees on an annual Department of Defense (DOD) appropriations bill, …

Add your voice to FPN’s to encourage more government research spending on peripheral neuropathy Read More »

FDA and FPN survey patients on chronic pain and treatments

Leave a Comment / Advocacy, Exercise, News / By

On July 9, 2018, the Federal Drug Administration (FDA) held a public forum focusing on the patient’s perspective on drug development for chronic pain. The FDA invited members of the public, including the Foundation for Peripheral Neuropathy’s (FPN) President, Lou Mazawey, to attend to give their perspectives on living with chronic pain and treatment approaches …

FDA and FPN survey patients on chronic pain and treatments Read More »

FPN Connects Peripheral Neuropathy Researchers at Astellas Pharma to the Patients They Are Hoping to Serve

Advocacy, Diabetic Peripheral Neuropathy, News, Research / By

On December 3, 2015, Astellas Pharma US, Inc. (the U.S. affiliate of Astellas Pharma Inc.), a R&D-driven global pharmaceutical company, invited the Foundation for Peripheral Neuropathy to present to a global team working on development of ASP3662 for patients with neuropathic pain (NP). This was an internal meeting, which included Ulf Tollemar, Executive Director, Development …

FPN Connects Peripheral Neuropathy Researchers at Astellas Pharma to the Patients They Are Hoping to Serve Read More »